From: Clinical aspects for differential diagnosis of Kawasaki disease shock syndrome: a case control study
KDSS(n=13) | KD(n=91) | P value | |
---|---|---|---|
Kawasaki features | |||
Conjunctival injection | 92.3% (12/13) | 91.2% (83/91) | 1.000 |
Oropharyngeal changes | 84.6% (11/13) | 81.3% (74/91) | 1.000 |
Polymorphous rash | 76.9% (10/13) | 84.6% (77/91) | 0.442 |
Cervical lymphadenopathy | 69.2% (9/13) | 44.0% (40/91) | 0.088 |
Extremity changes | 92.3% (12/13) | 67.0% (61/91) | 0.102 |
Associated symptoms | |||
Gastrointestinal symptoms | 84.6% (11/13) | 26.4% (24/91) | 0.000 |
Respiratory symptoms | 76.9% (10/13) | 9.9% (9/91) | 0.000 |
Neurologic symptoms | 15.4% (2/13) | 2.2% (2/91) | 0.066 |
Systemic pain | 53.8% (7/13) | 3.3% (3/91) | 0.000 |
Pleural effusion | 76.9% (10/13) | 2.2% (2/91) | 0.000 |
Organ damage | 92.3% (12/13) | 20.9%(19/91) | 0.000 |